Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Net Income From Continuing Operations : ¥-279.9 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Suzhou Zelgen Biopharmaceuticals Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Suzhou Zelgen Biopharmaceuticals Co's net income from continuing operations for the three months ended in Mar. 2024 was ¥-44.6 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was ¥-279.9 Mil.

Suzhou Zelgen Biopharmaceuticals Co Net Income From Continuing Operations Historical Data

The historical data trend for Suzhou Zelgen Biopharmaceuticals Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Suzhou Zelgen Biopharmaceuticals Co Net Income From Continuing Operations Chart

Suzhou Zelgen Biopharmaceuticals Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

-447.98

-310.68

-461.99

-485.51

-295.14

Suzhou Zelgen Biopharmaceuticals Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income From Continuing Operations	Get a 7-Day Free Trial															-59.88	-60.93	-93.49	-80.84	-44.63

Suzhou Zelgen Biopharmaceuticals Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-279.9 Mil.

Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Suzhou Zelgen Biopharmaceuticals Co Ltd (SHSE:688266) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.209 Chenfeng Road, Yushan Town, Jiangsu Province, Kunshan, CHN

Website

http://www.zelgen.com

Suzhou Zelgen Biopharmaceuticals Co Ltd is engaged in research and development of new chemical and biological drugs for various therapeutic areas, including tumors, bleeding and blood diseases, and hepatobiliary diseases.

Executives

Zhang Bin	Core technical personnel
Huang Gang	senior management
Lv Bin Hua	Directors, senior managers, core technical personn
Lu Hui Ping	Directors, senior managers
Gao Qing Ping	senior management
Wu Ji Sheng	Directors, senior managers, core technical personn
Zhang Jun Li	senior management
Wu Li Qing	Core technical personnel
	Core technical personnel
Sheng Ze Lin	Directors, senior managers, core technical personn

Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Headlines

No Headlines